PAREXEL International Strengthens Outcomes Research Capabilities to Help Biopharma Meet Commercialization Goals

BOSTON, Aug. 2, 2012 /PRNewswire/ -- PAREXEL Consulting, a business unit of PAREXEL International (NASDAQ: PRXL) and a leading global consultancy serving the biopharmaceutical and medical device industries, today announced that Leanne R. Larson has been appointed as Vice President, Evidence Development. The new position demonstrates a continuing commitment from PAREXEL in the area of Outcomes Research. Ms. Larson’s expertise in strategy, design, implementation, and analysis of patient registries and outcomes research programs will further support clients in meeting the needs of payors, regulators, physicians, and patients when making treatment decisions.

Ms. Larson has more than twenty-five years’ experience in healthcare, featuring extensive work in pharmaceutical product development and marketing, and in healthcare technology and operational consulting. For nearly twenty years, she has been an industry thought leader in developing and implementing patient registries and in advancing the science and application of outcomes research. Prior to joining PAREXEL, Ms. Larson served more than 15 years in senior and strategic roles within Clinical Research Organizations. She has also held positions in Ernst & Young’s Life Sciences and Pharmaceuticals consulting practice, as well as Merck and Co.'s Health Sciences-Digestive Disease group.

“Leanne Larson is a great addition to PAREXEL. Bringing on board an industry leader of her caliber further strengthens our recognized team of experts,” said Ron Kraus, Corporate Vice President & Worldwide Head of PAREXEL Consulting and Medical Communications Services. “We eagerly look forward to applying her deep knowledge and experience to support our clients in successfully commercializing their products.”

Larson received her Master of Health Administration (MHA) from Governors State University and a Bachelor of Science in Community Health from the University of Illinois. She is also an Instructor in Health Service Systems at the Keller Graduate School of Management, and is a Charter Member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), as well as an Invited Reviewer for The Center for Disease Control and Prevention (CDC).

PAREXEL Consulting provides integrated product development consulting services, helping biopharmaceutical companies shorten time to market and maintain product viability in developed and emerging markets. Expertise provided by PAREXEL Consulting includes strategic regulatory guidance, product globalization, and development optimization to effectively align development and commercialization strategies. PAREXEL Consulting experts also provide capabilities in development of leading edge products such as biosimilars, therapeutic vaccines, and combination products. For information regarding PAREXEL consulting services visit http://www.parexel.com

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation